Trial Profile
A Phase 3 Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Subjects With Primary Mitochondrial Myopathy Followed by an Open-Label Treatment Extension
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 06 Jun 2023
Price :
$35
*
At a glance
- Drugs Elamipretide (Primary)
- Indications Mitochondrial myopathies
- Focus Registrational; Therapeutic Use
- Acronyms MMPOWER-3
- Sponsors Stealth BioTherapeutics
- 02 Jun 2023 Results assessing Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy published in the Neurology
- 18 May 2021 According to a Stealth BioTherapeutics media release, Company plans to initiate a new phase 3 trial by year end upon meeting with DRDMG during the third quarter of 2021in patients who appeared to respond to elamipretide therapy from this trial.
- 09 Dec 2020 According to a Stealth Biotech media release, data from this study will be presented at the upcoming 13th International Conference on Cachexia, Sarcopenia and Wasting Diseases being held online from December 11-13, 2020.